DEA Judge Rejects Bid to Reopen Cannabis Rescheduling Hearing, Sets November 5 Deadline

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

DEA Chief Administrative Law Judge Derek C. Julius denied opponents' bid for more discovery and testimony in the marijuana rescheduling proceeding, but allowed limited briefing on a GAO report, with replies due November 5 and no deadline for a final decision.

• Operators: Another round of discovery is avoided, but broader Schedule III timing stays open. Section 280E relief for operators outside the narrower April 2026 medical rule remains uncertain, so tax and cash-flow planning should not assume a date.
• Investors: One source of procedural delay is removed, yet no deadline exists for the judge's recommendation or DEA's final decision. A separate D.C. Circuit challenge to the April 2026 order could run into 2027.
• Do now: Mark October 29 and November 5 on your calendar, and keep forecasts separate for the existing April 2026 medical rule and the still-unresolved broader Schedule III proposal.

Short on time? You’re done. Want the numbers?Keep reading ↓

The federal marijuana rescheduling process has cleared another procedural hurdle, but a new briefing schedule will keep the administrative proceedings on hold until two days after the November 3 midterm elections.

On Thursday, October 22, Drug Enforcement Administration (DEA) Chief Administrative Law Judge Derek C. Julius denied opponents’ request for additional discovery and testimony in the proceeding to move marijuana from Schedule I to Schedule III of the Controlled Substances Act.

However, Julius agreed to admit a September report from the Government Accountability Office (GAO) into the administrative record and authorized limited supplemental briefing on whether its findings could undermine the federal government’s rescheduling proposal.

Initial briefs are due October 29, with optional replies due November 5. The judge ordered that the current stay expire automatically once the briefing period concludes.

The ruling follows DEA’s October 20 opposition to reopening the hearing, in which the agency characterized opponents’ discovery requests as a “fishing expedition.”

For cannabis companies awaiting broader federal rescheduling, the decision removes the immediate prospect of another round of testimony while leaving the timing of a final regulatory decision unresolved.

Judge Rejects Additional Discovery and Testimony

The dispute emerged after opponents of marijuana rescheduling sought to reopen the evidentiary hearing following the publication of a September 23 GAO report examining deficiencies in federal drug scheduling procedures.

DUID Victim Voices, physician Kenneth Finn and the National Drug and Alcohol Screening Association (NDASA) requested additional documents and testimony concerning the development of the federal government’s medical-use standard, its assessment of marijuana’s abuse potential and the procedures underlying the Department of Health and Human Services’ (HHS) recommendation.

DEA opposed the request, arguing that the parties had already been given opportunities to examine the scientific evidence and question federal officials during hearings held between June 29 and July 15.

Julius sided with the agency on reopening the hearing.

The judge found that the opponents had not established sufficient grounds to conduct additional discovery or introduce further testimony. The existing record includes extensive witness testimony and documentary evidence addressing the federal government’s scientific and medical evaluation.

His decision does not determine whether the government’s underlying rescheduling proposal is legally or scientifically justified. Instead, it limits the evidence-gathering phase of the administrative proceeding.

GAO Report Admitted, but Its Significance Remains Disputed

Although Julius rejected additional discovery, he admitted the GAO report into evidence as Finn Exhibit 126.

The September report found that DEA and the Food and Drug Administration (FDA) lacked comprehensive written policies and procedures governing important aspects of their drug scheduling evaluations.

However, the watchdog did not conclude that the marijuana rescheduling proposal was invalid or that the scientific evaluation supporting it was incorrect.

The central dispute now concerns what significance those procedural deficiencies should have in the pending marijuana proceeding.

In his October 22 order, Julius observed that the government’s position and the arguments advanced by rescheduling opponents were not necessarily as different as their filings suggested.

“The Moving Parties and the Government appear closer aligned in their understanding of the GAO Report than their postures may indicate,” he wrote.

The judge’s decision to permit supplemental briefing gives the parties a final opportunity to explain whether the GAO findings should affect the outcome of the proceeding.

It does not authorize another evidentiary hearing.

October 29 and November 5: What Happens Next?

Under the new schedule, interested parties may submit optional supplemental briefs by October 29, followed by optional replies on November 5.

The submissions are limited to ten double-spaced pages and must address the weight of the GAO report and whether its findings could affect the rescheduling proposal.

Julius indicated that requests for additional briefing beyond those deadlines would be disfavored.

Importantly, the judge also ordered that the existing stay expire automatically when the briefing period concludes.

That does not mean marijuana will be rescheduled on November 5.

The expiration of the stay allows the administrative proceeding to move forward. Julius must still complete his consideration of the record and issue his recommendation before DEA leadership makes a final decision on the broader rescheduling proposal.

The October 22 order does not establish a deadline for either action.

Rescheduling Proceedings Extend Beyond the Midterm Elections

The November 5 deadline falls two days after the November 3 U.S. midterm elections, extending the current procedural pause beyond an important political milestone.

Marijuana rescheduling has remained a significant federal policy issue, with potential consequences for cannabis businesses, investors and the administration’s broader drug policy agenda.

However, the timing should not be confused with evidence that DEA or the judge sought to align the proceedings with the election calendar.

The October 22 order addresses an evidentiary dispute, not electoral considerations.

From a regulatory perspective, the decision reflects a compromise between competing procedural concerns: preventing additional discovery from extending the hearing while allowing the parties to address a federal oversight report that could become relevant in subsequent legal challenges.

The additional briefing could strengthen the administrative record by clarifying how the agency considered the GAO’s findings.

Whether it ultimately affects the rescheduling recommendation remains uncertain.

Separate Federal Court Challenge Could Continue Into 2027

The administrative proceeding is not the only legal process affecting federal marijuana policy.

As IgniteIt previously reported, a separate consolidated challenge before the U.S. Court of Appeals for the D.C. Circuit concerns the administration’s April 2026 order transferring certain qualifying medical marijuana products into Schedule III.

The Justice Department and the challengers submitted a proposed briefing schedule under which opening briefs would be due November 24, the government’s response January 13, 2027, and final written submissions February 19.

That timetable remains subject to court approval.

The distinction between the proceedings is important.

The appeals court litigation concerns the legality of the existing, narrower medical marijuana reclassification, while the DEA administrative proceeding addresses the proposed broader transfer of marijuana to Schedule III.

The October 22 ruling does not resolve the appeals court challenge, and the proposed February 19 deadline is not a deadline for DEA to finalize broader rescheduling.

What the Decision Means for Cannabis Operators

For cannabis companies, the immediate significance of the ruling is that another potentially lengthy round of discovery has been avoided.

However, the uncertainty surrounding the broader Schedule III proposal remains.

Section 280E of the Internal Revenue Code generally prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary and necessary business expenses for federal income tax purposes.

A broader transfer of marijuana to Schedule III could therefore materially affect the tax position, cash flow and profitability of operators whose activities would fall within the new classification.

The April 2026 rule already provides Schedule III treatment for certain qualifying medical marijuana products, but its narrower scope and ongoing litigation make it important to distinguish existing regulatory treatment from the potential consequences of broader rescheduling.

For publicly traded operators, those distinctions affect tax planning, capital allocation, debt management and financial forecasts.

The latest ruling reduces one source of procedural uncertainty without eliminating the larger regulatory risks.

With further discovery and testimony denied, the next milestones are the October 29 briefs, the November 5 replies and the judge’s eventual recommendation.

The administrative process now has a clearer path forward, but the industry still has no definitive date for a final decision on broader marijuana rescheduling.